AC
ANTX icon

Almitas Capital’s AN2 Therapeutics ANTX Stock Holding History

Almitas Capital’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.06M Hold
1,479,129
– – 1.14% 20
2025
Q4 		$1.69M Buy
1,479,129
+50,806
+4% +$59.3K 0.37% 45
2025
Q3 		$1.81M Hold
1,428,323
– – 0.42% 37
2025
Q2 		$1.51M Buy
1,428,323
+115,212
+9% +$137K 0.38% 39
2025
Q1 		$1.79M Hold
1,313,111
– – 0.59% 35
2024
Q4 		$1.81M Buy
+1,313,111
New +$1.59M 0.4% 44

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Almitas Capital's ANTX Position: Q1 2026 in Review

Almitas Capital held its AN2 Therapeutics (ANTX) position steady in Q1 2026 at 1,479,129 shares worth $5.06M. The position accounts for 1.14% of the portfolio, ranked #20.

Almitas Capital first reported a position in ANTX in Q4 2024 and has held it in 6 quarters since. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Almitas Capital held 1,479,129 shares of AN2 Therapeutics worth $5.06M as of Q1 2026.
  • Almitas Capital left its AN2 Therapeutics share count unchanged in Q1 2026.
  • AN2 Therapeutics made up 1.14% of Almitas Capital's portfolio in Q1 2026, its #20 holding.
  • Almitas Capital first reported a position in AN2 Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Almitas Capital's 13F filing for Q1 2026, filed 15 May 2026.